BMY vs MRK · P/E 17, rev $24.46B vs P/E 33, rev $16.61B
Bristol-Myers Squibb Company (BMY) versus Merck & Company Inc (MRK) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Christopher S. Boerner Ph.D..
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Robert M. Davis J.D..
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Not investment advice. Open the BMY and MRK stock pages for the full models.
Not investment advice.